FCGR3A and neoplasm: In the current study, we demonstrated for the first time, in wild-type RAS mCRC patients, a significant relationship between the density of FcγRIIIa+ (FcγRIIIA+ (CD16) intraepithelial TAN in close contact with tumor cells in metastases and the objective response to cetuximab.